openPR Logo
Press release

Meningioma Market is Expected to Show a Healthy Growth Rate During the Study Period (2019-2032)| Key Companies - Arno Therapeutics Inc, AstraZeneca Plc, Boehringer Ingelheim GmbH, Eli Lilly, Genentech, GlaxoSmithKline

08-25-2023 01:11 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

DelveInsight's "Meningioma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Meningioma, historical and forecasted epidemiology as well as the Meningioma market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Download Sample Report to know more @ https://www.delveinsight.com/sample-request/meningioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

Meningioma Overview
Meningioma, also known as meningeal tumor, is typically a slow-growing tumor that forms from the meninges, the membranous layers surrounding the brain and spinal cord.
Symptoms depend on the location and occur as a result of the tumor pressing on nearby tissue. Many cases never produce symptoms. Occasionally seizures, dementia, trouble talking, vision problems, one-sided weakness, or loss of bladder control may occur.

Risk factors include exposure to ionizing radiation such as during radiation therapy, a family history of the condition, and neurofibromatosis type 2. They appear to be able to form from a number of different types of cells including arachnoid cells. Diagnosis is typically by medical imaging.
If there are no symptoms, periodic observation may be all that is required. Most cases that result in symptoms can be cured by surgery. Following complete removal fewer than 20% recur. If surgery is not possible or the tumor cannot be removed, radiosurgery may be helpful. Chemotherapy has not been found to be useful. A small percentage grows rapidly and is associated with worse outcomes.

Click here to learn more about the Meningioma Market Landscape @https://www.delveinsight.com/report-store/meningioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

Key Highlights from the Meningioma Market Report
Key Companies working in the Meningioma market include Arno Therapeutics Inc, AstraZeneca Plc, Boehringer Ingelheim GmbH, Eli Lilly, Genentech, GlaxoSmithKline Plc, and many others.
Key Therapies involved in the Meningioma market include Cu-64 SARTATE, SOM230C, Lutathera, Trametinib, Alpelisib, Trametinib, and many others.


Meningioma Treatment Market
After surgery, radiation is often recommended to delay the return of grade II and III meningiomas. Treatments may also include chemotherapy or clinical trials. Clinical trials, with new chemotherapy, targeted therapy, or immunotherapy drugs, may also be available and can be a possible treatment option.

Learn more about the treatment market for Meningioma @ https://www.delveinsight.com/report-store/meningioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

The Report Covers the Meningioma Epidemiology Segmented by:
Meningioma prevalent cases
Meningioma Incident Cases
Meningioma treatment cases
Meningioma diagnosed cases

Meningioma Key Companies
Arno Therapeutics Inc
AstraZeneca Plc
Boehringer Ingelheim GmbH
Eli Lilly
Genentech
GlaxoSmithKline Plc

Learn more about the Key Companies and Emerging Therapies in the Meningioma Market @https://www.delveinsight.com/report-store/meningioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

Table of Contents
Key Insights
Meningioma Introduction
Executive Summary of Meningioma
Disease Background and Overview
Meningioma Epidemiology and Patient Population
Meningioma Emerging Therapies
Meningioma Market Outlook
Meningioma Market Access and Reimbursement of Therapies
Meningioma Market Drivers
Meningioma Market Barriers
Appendix
Meningioma Report Methodology
DelveInsight Capabilities
Disclaimer

Learn about the detailed offerings of the Meningioma Market Outlook report @ https://www.delveinsight.com/report-store/meningioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

Related Reports

Meningioma Epidemiology Forecast
https://www.delveinsight.com/report-store/meningioma-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

Meningioma Pipeline Forecast
https://www.delveinsight.com/report-store/meningioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

DelveInsight Business Research LLP
Adya Kaul
info@delveinsight.com
https://www.delveinsight.com

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Meningioma Market is Expected to Show a Healthy Growth Rate During the Study Period (2019-2032)| Key Companies - Arno Therapeutics Inc, AstraZeneca Plc, Boehringer Ingelheim GmbH, Eli Lilly, Genentech, GlaxoSmithKline here

News-ID: 3181913 • Views:

More Releases from DelveInsight Business Research LLP

Liver Fibrosis Market Size in the 7MM is projected to grow at a CAGR of 23.9% by 2034, estimates DelveInsight
Liver Fibrosis Market Size in the 7MM is projected to grow at a CAGR of 23.9% by …
DelveInsight's "Liver Fibrosis Market Insight, Epidemiology and Market Forecast - 2034" report delivers an in-depth analysis of Liver Fibrosis epidemiology, market, and clinical development understanding, Addition to this report provides historical and forecasted epidemiology and market data as well as a detailed analysis on the Liver Fibrosis therapeutics market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan. Download DelveInsight's comprehensive report to
Intratumoral Cancer Therapies Market Size in the 7MM is projected to grow at a CAGR of 49.10% by 2034, estimates DelveInsight
Intratumoral Cancer Therapies Market Size in the 7MM is projected to grow at a C …
DelveInsight's "Intratumoral Cancer Therapies Market Insight, Epidemiology and Market Forecast - 2034" report delivers an in-depth analysis of Intratumoral Cancer Therapies epidemiology, market, and clinical development understanding, Addition to this report provides historical and forecasted epidemiology and market data as well as a detailed analysis on the Intratumoral Cancer Therapies therapeutics market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan. Download DelveInsight's
Paroxysmal Nocturnal Hemoglobinuria Treatment Pipeline Shows Strong Momentum as 20+ Pharma Companies in the Race | DelveInsight
Paroxysmal Nocturnal Hemoglobinuria Treatment Pipeline Shows Strong Momentum as …
DelveInsight's, "Paroxysmal Nocturnal Haemoglobinuria Pipeline Insight 2026" report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Paroxysmal Nocturnal Haemoglobinuria pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead
Sarcopenia Clinical Trial Pipeline Appears Robust With 18+ Key Pharma Companies Actively Working in the Domain | DelveInsight
Sarcopenia Clinical Trial Pipeline Appears Robust With 18+ Key Pharma Companies …
DelveInsight's "Sarcopenia Pipeline Insight 2026" report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in the Sarcopenia pipeline landscape. It covers the Sarcopenia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Sarcopenia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore our latest breakthroughs in Sarcopenia Research. Learn more about

All 5 Releases


More Releases for Meningioma

Meningioma Pipeline Appears Robust With 5+ Key Pharma Companies Actively Working …
DelveInsight's, "Meningioma Pipeline Insight 2025" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Meningioma pipeline landscape. It covers the Meningioma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Meningioma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Meningioma
Meningioma Market Report 2032: Epidemiology Analysis, Treatment drugs, FDA Appro …
DelveInsight's "Meningioma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Meningioma, historical and forecasted epidemiology as well as the Meningioma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Meningioma market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Meningioma market size from 2019 to 2032, segmented by
Comprehensive Analysis of Meningioma Market 2032: Epidemiological Insights, Trea …
(Albany, USA) DelveInsight's "Meningioma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Meningioma, historical and forecasted epidemiology as well as the Meningioma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Meningioma market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Meningioma market size from 2019 to 2032,
Meningioma Market Report 2032: Epidemiology Analysis, Treatment drugs, FDA Appro …
(Albany, USA) DelveInsight's "Meningioma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Meningioma, historical and forecasted epidemiology as well as the Meningioma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Meningioma market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Meningioma market size from 2019 to
Meningioma Market is Expected to Show a Healthy Growth Rate During the Study Per …
DelveInsight's "Meningioma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Meningioma, historical and forecasted epidemiology as well as the Meningioma market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Download Sample Report to know more @ https://www.delveinsight.com/sample-request/meningioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr Meningioma Overview Meningioma, also known as meningeal tumor, is typically a slow-growing tumor that forms from the meninges, the membranous layers surrounding the
Meningioma Market to Witness Growth by 2032, Estimates DelveInsight | Companies- …
DelveInsight's "Meningioma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Meningioma, historical and forecasted epidemiology as well as the Meningioma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Meningioma market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Meningioma market size from 2019 to 2032, segmented